Hybrid PET/CT in Cancer Patients

This study has been completed.

Sponsor:

Information provided by:

Rambam Health Care Campus

ClinicalTrials.gov Identifier:

NCT00396916

First received: November 7, 2006

Last updated: April 10, 2007

Last verified: April 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

November 7, 2006

Last Updated Date

April 10, 2007

Start Date ^ICMJE

December 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

the impact of the imaging modality on patient management

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00396916 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

the impact of the imaging modality on patient management

Original Secondary Outcome Measures ^ICMJE

Same as current

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Hybrid PET/CT in Cancer Patients

Official Title ^ICMJE

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

Brief Summary

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Condition ^ICMJE

Cancer

Intervention ^ICMJE

Device: PET/CT imaging

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
Patients with newly diagnosed metastatic cancer with unknown primary tumor
Glucose levels below 150-200
Patient signed informed consent

Exclusion Criteria:

Pregnant or lactating women
Patient unable or not willing to tolerate the test until its completion
One or more of the inclusion criteria is not fulfilled

Gender

Both

Ages

Not Provided

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Israel

Administrative Information

NCT Number ^ICMJE

NCT00396916

Other Study ID Numbers ^ICMJE

hybridCTIL

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Rambam Health Care Campus

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Rachel Bar-Shalom, MD

Rambam Health Care Campus

Information Provided By

Rambam Health Care Campus

Verification Date

April 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top